Marinomed Biotech AG
Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms
DGAP-News: Marinomed Biotech AG
/ Key word(s): Study
Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms
Korneuburg, Austria, 12 April 2021 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial[1] evaluating Tacrosolv eye drops in allergic rhinoconjunctivitis, i. e. hay fever affecting both the eyes and nose. The randomized, placebo controlled, double-blind phase II clinical trial was conducted at the Vienna Challenge Chamber (Austria) to assess safety and efficacy of two different dosages of Tacrosolv in a crossover design. Positive results provided, the Company plans to extend the ophthalmic use of Tacrosolv to further indications beyond allergic symptoms such as dry eye disease (keratoconjunctivitis sicca) and other types of ocular inflammation. “We are very pleased to conclude the active part of our phase II Tacrosolv. We are confident that the results will support our hypothesis that Tacrosolv is the first formulation of this highly potent immunosuppressant that allows for its use as an effective therapy in ocular inflammation,” said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed. “Formulated with Marinosolv, we could achieve a more than 200-fold higher solubility compared to water enabling the use of tacrolimus in eye drops. Moreover, our formulation has a high local bioavailability – characteristics we have seen for several Marinosolv formulations so far.” Tacrosolv is an improved formulation of tacrolimus, an immunomodulator that can suppress inflammatory reactions, including allergic symptoms. The now off-patent blockbuster drug is poorly soluble, so far limiting its usefulness for ophthalmic applications. Allergic rhinitis and allergic rhinoconjunctivitis (hay fever) are extremely common conditions, affecting up to 25 % of people in Europe.[2] While not life-threatening, hay fever severely impacts patients’ quality of life.[3],[4] According to experts, socioeconomic costs of up to €84 billion per year could be saved with adequate treatment of allergies in the European Union.[5] About Marinosolv(R): About Marinomed Biotech AG References
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
12.04.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |